Karen K Winer1, Andrea Kelly2, Alicia Johns3, Bo Zhang3, Karen Dowdy4, Lauren Kim4, James C Reynolds4, Paul S Albert5, Gordon B Cutler3. 1. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD. Electronic address: winerk@mail.nih.gov. 2. Division of Endocrinology, Children's Hospital of Philadelphia, Philadelphia, PA. 3. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD. 4. National Institutes of Health Clinical Center, Radiology and Imaging Sciences, Bethesda, MD. 5. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Abstract
OBJECTIVE: To determine whether multiple daily injections of parathyroid hormone (PTH) 1-34 are safe and effective as long-term therapy for children with hypoparathyroidism. STUDY DESIGN: Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children. METHODS: Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years). Mean daily PTH 1-34 dose was 0.75 ± 0.15 µg/kg/day. Treatment duration was 6.9 ± 3.1 years (range 1.5-10 years). Patients were evaluated semiannually at the National Institutes of Health Clinical Center. RESULTS: Mean height velocity and lumbar spine, whole body, and femoral neck bone accretion velocities were normal throughout the study. In the first 2 years, distal one-third radius bone accrual velocity was reduced compared with normal children (P < .003). Serum alkaline phosphatase correlated with PTH 1-34 dose (P < .006) and remained normal (235.3 ± 104.8 [SD] U/L, N: 51-332 U/L). Mean serum and 24-hour urine calcium levels were 2.05 ± 0.11 mmol/L (N: 2.05-2.5 mmol/L) and 6.93 ± 1.3 mmol/24 hour (N: 1.25-7.5 mmol/24 hour), respectively-with fewer high urine calcium levels vs baseline during calcitriol and calcium treatment (P < .001). Nephrocalcinosis progressed in 5 of 12 subjects who had repeated renal imaging although renal function remained normal. CONCLUSIONS: Twice-daily or thrice-daily subcutaneous PTH 1-34 injections provided safe and effective replacement therapy for up to 10 years in children with hypoparathyroidism because of autoimmune polyglandular syndrome type 1 or calcium receptor mutation. Published by Elsevier Inc.
OBJECTIVE: To determine whether multiple daily injections of parathyroid hormone (PTH) 1-34 are safe and effective as long-term therapy for children with hypoparathyroidism. STUDY DESIGN: Linear growth, bone accrual, renal function, and mineral homeostasis were studied in a long-term observational study of PTH 1-34 injection therapy in 14 children. METHODS: Subjects were 14 children with hypoparathyroidism attributable to autoimmune polyglandular syndrome type 1 (N = 5, ages 7-12 years) or calcium receptor mutation (N = 9, ages 7-16 years). Mean daily PTH 1-34 dose was 0.75 ± 0.15 µg/kg/day. Treatment duration was 6.9 ± 3.1 years (range 1.5-10 years). Patients were evaluated semiannually at the National Institutes of Health Clinical Center. RESULTS: Mean height velocity and lumbar spine, whole body, and femoral neck bone accretion velocities were normal throughout the study. In the first 2 years, distal one-third radius bone accrual velocity was reduced compared with normal children (P < .003). Serum alkaline phosphatase correlated with PTH 1-34 dose (P < .006) and remained normal (235.3 ± 104.8 [SD] U/L, N: 51-332 U/L). Mean serum and 24-hour urine calcium levels were 2.05 ± 0.11 mmol/L (N: 2.05-2.5 mmol/L) and 6.93 ± 1.3 mmol/24 hour (N: 1.25-7.5 mmol/24 hour), respectively-with fewer high urine calcium levels vs baseline during calcitriol and calcium treatment (P < .001). Nephrocalcinosis progressed in 5 of 12 subjects who had repeated renal imaging although renal function remained normal. CONCLUSIONS: Twice-daily or thrice-daily subcutaneous PTH 1-34 injections provided safe and effective replacement therapy for up to 10 years in children with hypoparathyroidism because of autoimmune polyglandular syndrome type 1 or calcium receptor mutation. Published by Elsevier Inc.
Authors: Katrin Uhlig; Jeffrey S Berns; Bryan Kestenbaum; Raj Kumar; Mary B Leonard; Kevin J Martin; Stuart M Sprague; Stanley Goldfarb Journal: Am J Kidney Dis Date: 2010-04-03 Impact factor: 8.860
Authors: Jens Bollerslev; Lars Rejnmark; Claudio Marcocci; Dolores M Shoback; Antonio Sitges-Serra; Wim van Biesen; Olaf M Dekkers Journal: Eur J Endocrinol Date: 2015-08 Impact factor: 6.664
Authors: A Lienhardt; M Bai; J P Lagarde; M Rigaud; Z Zhang; Y Jiang; M L Kottler; E M Brown; M Garabédian Journal: J Clin Endocrinol Metab Date: 2001-11 Impact factor: 5.958
Authors: Alison M Boyce; Thomas H Shawker; Suvimol C Hill; Peter L Choyke; Michael C Hill; Robert James; Nancy A Yovetich; Michael T Collins; Rachel I Gafni Journal: J Clin Endocrinol Metab Date: 2013-01-24 Impact factor: 5.958
Authors: Mishaela R Rubin; David W Dempster; Hua Zhou; Elizabeth Shane; Thomas Nickolas; James Sliney; Shonni J Silverberg; John P Bilezikian Journal: J Bone Miner Res Date: 2008-12 Impact factor: 6.741
Authors: Babette S Zemel; Mary B Leonard; Andrea Kelly; Joan M Lappe; Vicente Gilsanz; Sharon Oberfield; Soroosh Mahboubi; John A Shepherd; Thomas N Hangartner; Margaret M Frederick; Karen K Winer; Heidi J Kalkwarf Journal: J Clin Endocrinol Metab Date: 2010-01-26 Impact factor: 5.958
Authors: Laurie K McCauley; Nan E Hatch; Amy J Koh; Hwa Kyung Nam; Megan N Michalski; Justin Do Journal: Osteoporos Int Date: 2022-07-23 Impact factor: 5.071
Authors: Elena V Kovaleva; Anna K Eremkina; Alina R Elfimova; Julia A Krupinova; Ekaterina E Bibik; Irina S Maganeva; Anna M Gorbacheva; Ekaterina A Dobreva; Galina A Melnichenko; Natalia G Mokrysheva Journal: Front Endocrinol (Lausanne) Date: 2022-02-16 Impact factor: 5.555